Bortezomib-associated rash: A new recognizable and avoidable side-effect [20]

British Journal of Dermatology

Volumn 156, Issue 4, 2007, Pages 784-785

  Villarrubia, B ^a   Betlloch, I ^a   Mataix, J ^a   Lucas, A ^a   Botella, C ^a  

^a HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CHLORPHENIRAMINE; DEXAMETHASONE; DOXORUBICIN; HYDROXYZINE; PREDNISONE; VINCRISTINE;

ADULT; BACK; CANCER RELAPSE; CASE REPORT; DRUG ERUPTION; DRUG TOLERABILITY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LETTER; MALE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NECK; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PRIORITY JOURNAL; RECURRENT DISEASE; SKIN BIOPSY; TRUNK;

ANTINEOPLASTIC AGENTS; BORONIC ACIDS; DRUG ERUPTIONS; EXANTHEMA; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PYRAZINES;

EID: 33947379738     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2007.07757.x     Document Type: Letter

References (9)

1. Richardson PG, Barlogie B, Berenson J et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003; 348:2609-17.
2. Richardson PG, Sonneveld P, Schuster MW et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005; 352:2487-98.
3. Bladé J, Samson D, Reece D et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Br J Haematol 1998; 102:1115-23.
4. Kane RC, Farrel AT, Sridhara R, Pazdur R. United States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy. Clin Cancer Res 2006; 12:2955-60.
5. Pour L, Hajek R, Zdenek A et al. Skin lesions induced by bortezomib. Haematologica 2005; 90:10.
6. Agterof MJ, Biesma DH. Images in clinical medicine. Bortezomib-induced skin lesions. N Engl J Med 2005; 352:2534.
7. Wu KL, Heule F, Lam K, Sonneveld P. Pleomorphic presentation of cutaneous lesions associated with the proteasome inhibitor bortezomib in patients with multiple myeloma. J Am Acad Dermatol 2006; 55:897-900.
8. Gerecitano J, Goy A, Wright J et al. Drug-induced cutaneous vasculitis in patients with non-Hodgkin lymphoma treated with the novel proteasome inhibitor bortezomib: a possible surrogate marker of response? Br J Haematol 2006; 134:391-8.
9. Min CK, Lee S, Kim YJ et al. Cutaneous leucoclastic vasculitis (LV) following bortezomib therapy in a myeloma patient; association with pro-inflammatory cytokines. Eur J Haematol 2006; 76:265-8.